Observational analysis identifies risk factors for patients on bone-modifying drugs, suggesting early intervention is critical for MRONJ management.
As the number of pharmaceuticals implicated in medication-related osteonecrosis of the jaw (MRONJ) continues to increase, it is likely that the general dental practitioner (GDP) will encounter patients at risk of MRONJ in their practice. Part 1 gave a background to MRONJ and the management of patients planned for bone-modifying agents. Part 2 considers patients who are receiving bone-modifying agents and considers how to categorize their MRONJ risk as low or elevated. GDPs are suitably positioned to recognize the early signs and symptoms of MRONJ and promptly refer to secondary care for management. CPD/Clinical Relevance: Knowledge of how to manage patients who are taking bone-modifying drugs and are at risk of MRONJ is valuable.
No takes yet. Share an insight, caveat, or question.
Arya et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: